[Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature].
Kahl
K G
KG
Klinik für Psychiatrie und Psychotherapie, Universität Lübeck, 23538 Lübeck. kahl.k@psychiatry.uni-luebeck.de
Trillenberg
P
P
Kordon
A
A
Lencer
R
R
Klein
C
C
Hagenah
J
J
D000328:Adult; D001905:Botulinum Toxins / Q000008:administration & dosage*; D019274:Botulinum Toxins, Type A; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012798:Sialorrhea / Q000139:chemically induced* / Q000188:drug therapy*
D018727:Muscarinic Antagonists; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D003024:Clozapine
Therapie der Clozapin-induzierten Hypersalivation mit Botulinum-Toxin B.